Risks and Harms of Implementing this Recommendation
As with all surgical procedures, there are potential risks and complications, including, but not limited to, the possibility of bleeding. There is no data suggesting patient outcome harms will occur with implementation of this recommendation.
Future research with regard to risks and benefits of delayed surgery should include patient oriented outcome measures such as death, return to prior living situation and treatment complications such as transfusions, wound infections and return to operating room. Some of these factors may be addressed with treatment registries. It is also appropriate to address the risks and benefits of delayed surgery for patients on antiplatelet medication specific to this patient population and to quantify risks of those who are on these medicines (e.g. bleeding, transfusions, etc). Appropriately targeted randomized trials would be helpful.
- (34) Chechik O, Amar E, Khashan M, Kadar A, Rosenblatt Y, Maman E. In support of early surgery for hip fractures sustained by elderly patients taking clopidogrel: a retrospective study. Drugs Aging 2012;29(1):63-68.
- (35) Maheshwari R, Acharya M, Monda M, Pandey R. Factors influencing mortality in patients on antiplatelet agents presenting with proximal femoral fractures. J Orthop Surg (Hong Kong) 2011;19(3):314-316.
- (36) Manning BJ, O'Brien N, Aravindan S, Cahill RA, McGreal G, Redmond HP. The effect of aspirin on blood loss and transfusion requirements in patients with femoral neck fractures. Injury 2004;35(2):121-124.
- (37) Thaler HW, Frisee F, Korninger C. Platelet aggregation inhibitors, platelet function testing, and blood loss in hip fracture surgery. J Trauma 2010;69(5):1217-1220.
- (38) Hossain FS, Rambani R, Ribee H, Koch L. Is discontinuation of clopidogrel necessary for intracapsular hip fracture surgery? Analysis of 102 hemiarthroplasties. J Orthop Traumatol 2013.